- Trial phase
- Approved
- Time to market
- Already approved and commercially launched in the US (FDA approval December 2025, launch began February 2026). Also approved in China (September 2026).
- Why 4/10
- CARDAMYST is already FDA-approved and commercially launched, so there is no pending PDUFA or pivotal readout for the PSVT indication. The next hard catalyst is the Phase 3 ReVeRA-301 topline readout for AFib-RVR, but no specific date has been announced. As an approved drug with no imminent binary catalyst, the impact score is capped at 5.
CARDAMYST is already approved and launched, so the next major catalyst is the Phase 3 ReVeRA-301 topline readout for AFib-RVR, which could expand the addressable market significantly. The company's Q3 2026 earnings today showed accelerating prescription growth (73% sequential revenue increase) but also a 30% cost-cutting plan, and the stock fell ~20% on the day. Watch for quarterly prescription and revenue trends as the key near-term value drivers.
Price Chart
Executive Summary
CARDAMYST (etripamil) is a self-administered nasal spray approved by the FDA in December 2025 for paroxysmal supraventricular tachycardia (PSVT), a condition causing sudden episodes of rapid heart rate. It is the first at-home treatment option for PSVT in 30 years, offering an alternative to emergency room visits for intravenous drugs. Milestone Pharmaceuticals (MIST, Nasdaq) launched the drug commercially in early 2026. Q3 2026 results reported today showed 73% sequential revenue growth but the company is cutting costs by 30% to extend its cash runway. The stock has fallen from ~$3 pre-approval to $0.52, reflecting investor skepticism about commercial uptake against cheap generic alternatives. A Phase 3 trial for a second indication (AFib-RVR) is underway, and China approval was granted in September 2026.
How It Works
CARDAMYST (etripamil) is a rapid-acting L-type calcium channel blocker delivered as a nasal spray. It works by slowing the electrical signals in the heart that cause sudden episodes of rapid heart rate (paroxysmal supraventricular tachycardia, or PSVT). Patients self-administer the spray into each nostril at the onset of symptoms to convert the abnormal heart rhythm back to normal. It is the first FDA-approved drug that patients can use at home for this condition, rather than having to go to an emergency room for intravenous treatment.
Trial Status
CARDAMYST was FDA-approved in December 2025 based on Phase 3 clinical trials for PSVT. A Phase 4 registry (RESET-PSVT) is collecting real-world data. A separate Phase 3 registrational trial (ReVeRA-301) for atrial fibrillation with rapid ventricular rate (AFib-RVR) began enrolling in August 2026.
The Two-Sided Case
Upcoming Catalysts
- Phase 3 ReVeRA-301 topline readout for AFib-RVR (no specific date announced)
- Quarterly prescription and revenue growth updates as commercial launch matures
- Potential label expansion or additional real-world evidence from the RESET-PSVT registry
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Milestone Pharmaceuticals Inc. 8-K MIST ·Originating report